Between March and November 2025, GOSTAR Small Molecules continued steady, high-quality growth across compounds, SAR, ADMET, patents, and literature coverage. This release adds hundreds of thousands of compounds and over a million SAR data points, strengthening GOSTAR’s role as a trusted, manually curated source of small molecule SAR for medicinal chemistry, machine learning, and competitive landscape analysis workflows.
GOSTAR™ small molecules growth: march to november 2025
| Category | March 2025 | May 2025 | July 2025 | September 2025 | November 2025 | Net Growth (Mar–Nov) |
|---|---|---|---|---|---|---|
| Compounds | 10,634,943 | 10,797,536 | 10,838,334 | 10,936,188 | 11,041,219 | +406,276 |
| SAR Data Points | 35,658,374 | 36,131,100 | 36,282,470 | 36,538,765 | 36,799,903 | +1,141,529 |
| ADMET Data Points | 3,711,704 | 3,743,263 | 3,749,416 | 3,758,528 | 3,768,355 | +56,651 |
| Targets | 79,091 | 79,507 | 79,708 | 79,875 | 80,351 | +1,260 |
| Preclinical & Clinical Compounds | 59,715 | 59,722 | 59,617 | 60,123 | 60,422 | +707 |
| Patents | 99,656 | 101,084 | 101,383 | 102,020 | 102,600 | +2,944 |
| Journal Articles | 216,620 | 217,228 | 217,528 | 218,056 | 218,806 | +2,186 |
| Other Data Sources | 117,460 | 117,480 | 117,492 | 117,988 | 119,557 | +2,097 |
Summary of content changes
1. Increase in compound coverage
From 10.63M to 11.04M compounds, including 324,000+ new unique molecules, the databases’ chemical breadth continues to expand. These additions represent newly disclosed molecules in patents and literature, improved structure normalizations, and the integration of new series and analogues.
A larger structural diversity improves hit-finding, analogue searching, scaffold-hopping, and similarity-based prioritization, especially when teams are hunting novel chemotypes or looking for bio-isosteric replacements.
2. Over 1 million new SAR records
SAR data increased from 35.66M to 36.80M. These include well-annotated activity endpoints (IC₅₀/EC₅₀/Ki/MIC), selectivity panels, and assay context (cell line, exposure time, species).
A richer SAR density supports confident medicinal chemistry decisions (activity cliffs, tolerated substitutions), higher-quality QSAR/ML training sets, and more reliable structure-activity analysis used for lead optimization.
3. ADMET data expansion
ADMET entries rose from 3.71M to 3.77M. New records emphasize permeability, metabolic stability, CYP interactions, and in vivo PK where available.
ADMET signals feed early-stage developability triage and power predictive ML models for bioavailability, clearance, and safety liabilities, reducing costly late-stage failures.
4. Addition of new targets
Targets increased from 79,091 to 80,351. That reflects additions across GPCRs, kinases, ion channels, and other emerging biology.
A broader target space helps cross-target SAR analysis and supports target de-risking, polypharmacology searches, and target-class benchmarking.
5. Patents and literature continue to enrich IP intelligence
Patents grew from 99,656 to 102,600, and journal articles from 216,620 to 218,806. These updates include new patent filings across global jurisdictions and recent medicinal chemistry publications.
Better patent and literature coverage reveals first disclosures, chemical series evolution, and often unique experimental tables, critical for freedom-to-operate assessments, novelty checks, and competitive landscaping.
6. Clinical & preclinical compound mapping refined
Preclinical/clinical compound counts shifted from 59,715 to 60,422. The small increase reflects ongoing QA (deduplication, phase updates) and improved trial-compound linkages.
An accurate clinical compound mapping is essential for benchmarking, competitor monitoring, and translational risk assessment.
Value to our users
Medicinal chemists: richer SAR, ADMET, and structure coverage translates to higher-probability analogue suggestions and clearer potency/selectivity tradeoffs.
- Data scientists / ML teams: a million+ new SAR points mean larger, cleaner training sets and better external validation folds.
- IP and portfolio teams: more patents and linked structures improve novelty assessments and whitespace analyses.
- Project leads: improved target and clinical mappings make competitive benchmarking and go/no-go decisions more evidence-based.
Explore the update
Log in to your GOSTARᵀᴹ Small Molecules account to explore the latest data or contact our team for access to high-quality curated datasets.
